Introduction
Acute pain is common in emergency care, and is experienced by up to 90% of trauma patients. It is often undertreated in both prehospital and emergency department (ED) settings. 1, 2 Inadequate pain management is associated with physiological and psychological stress, which can impact therapy and rehabilitation, resulting in diminished quality of life of the patient. 3 Main analgesics in emergency settings include paracetamol, nonsteroidal anti-inflammatory drugs, ketamine, nitrous oxide (N 2 O), and opiates. 4 Recently, the inhalational analgesic low-dose methoxyflurane, which has been used extensively in emergency settings in Australia and New Zealand for over 30 years, was approved in some European countries (Belgium, France, Ireland, and the UK) for emergency relief of moderate-severe pain in conscious adult patients
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Porter et al with trauma and associated pain. Low-dose methoxyflurane is self-administered in analgesic doses at a maximum of two 3 mL vials in a single administration via a handheld inhaler; a green, whistle-shaped, single-use device. 5 It provides rapid, short-term pain relief (within six to ten inhalations), 5 and has been shown effective and safe in emergency care [6] [7] [8] [9] and for minor surgical, radiological, and dental procedures. 10, 11 Both low-dose methoxyflurane and N 2 O (50:50 with oxygen; "N 2 O" hereafter) are self-administered, self-titrated, rapid-acting, nonnarcotic, noninvasive inhalational agents with similar onset times of pain relief. 7, 12 Our systematic review of the literature found only a few controlled studies and no head-to-head trials of these two analgesics performed in the emergency setting. To compare clinical efficacy, safety, and tolerability in emergency care, we thus carried out an indirect treatment comparison.
Materials and methods
This systematic review was carried out and reported according to the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) guidelines. 13 
Literature search
Searches were undertaken from database inception to December 22, 2015 14 emergency and trauma-associated pain, and intervention, using both medical subject heading and free text terms (for detailed search strategies, see Tables S1 and S2 ).
Study selection
Studies were required to fulfill the following criteria to be included in the review: 1) a population of adult patients (≥18 years), 2) trauma-induced pain in the prehospital or hospital setting, 3) randomized controlled trial or observational study design, 4) intervention low-dose methoxyflurane and/ or N 2 O, and 5) English language publication. The screening process was performed independently by two reviewers; any disagreement was resolved by a third reviewer. Abstracts of all records identified in the search were checked for eligibility, and full-text copies of potentially relevant studies were rescreened.
Assessment of methodological quality
Risk-of-bias assessments were performed using the Cochrane Collaboration's tool (shown in Table S3 ). 15 Study grade for adequacy of concealment of random allocation and Jadad score for study quality and reporting 16 were also determined. To rule out the impact of clinical heterogeneity, studies were fully assessed for baseline comparability before they were included in the analysis.
Data extraction
Data extraction was carried out independently by two reviewers; a third reviewer resolved any disagreements. Information regarding study characteristics, type of pain scale employed, definition of pain relief, and patient data, including demographics, type and location of trauma, pain intensity at different time points, lack of pain relief, and occurrence of adverse events (AEs), was collected. Some of the pain-intensity and pain-relief data were extracted from illustrations in the relevant publications using graph digitization. Median pain scores from one study were obtained by post hoc calculations. 8 
Outcome parameters
The primary efficacy outcome was change in pain intensity under pain medication from baseline at 5, 10, and 15 minutes after start of inhalation, as measured by the 11-point numeric rating scale (NRS; from 0 = no pain to 10 = worst imaginable pain) or the 100 mm visual analog scale (VAS; from 0 = no pain to 100 = worst pain). As these pain scales are interchangeable for acute-pain measurements in the ED 17, 18 but not interconvertible, the ensuing risk of variability was reduced by calculating standardized median differences with 95% CIs between treatments for change in pain intensity from baseline instead of weighted mean differences. As a second outcome, the proportion of patients experiencing no pain relief under study medication was calculated. AE documentation was used for tolerability assessment.
Statistical analysis
Statistical analyses were performed using Stata for Windows (version 11.0; StataCorp, College Station, TX, USA). We did not identify any head-to-head clinical trial between low-dose methoxyflurane and N 2 O in our systematic review. Adjusted indirect comparison has been increasingly used in systematic reviews to evaluate relative effects of interventions, due to a lack of head-to-head randomized trials. As the evidence network included only two studies connected through a bridging comparator (placebo), adjusted indirect treatment comparison using the method by Bucher et al 19 was conducted. Indirect comparison methods are used to measure the effect of treatment A compared with treatment B based on the results of trials of A and of B versus the same control (placebo or active treatment). These methods provide extrapolations based on the hypothesis that the effects that A and B would have (compared with a control in a head-tohead trial) are the same as those observed in trials used in the indirect comparison. 19, 20 For the adjusted indirect comparison of intervention A versus intervention B to be valid, trials that compare intervention A versus placebo should be on average similar to trials that compare intervention B versus placebo in terms of moderators of relative treatment effect (baseline characteristics). The significance for treatment differences in this indirect comparison was at the two-sided 5% level.
Results

Search results and study selection
Literature searches yielded 808 references, which included 120 duplicates ( Figure 1 ). Twenty publications were deemed eligible; however, further assessment revealed that the eleven included observational studies did not provide data suitable for a quantitative efficacy analysis. These studies were thus excluded, leaving four randomized controlled trials 7, 12, 21, 22 for analysis. 
Qualitative assessment
Two of the studies 7, 12 were well conducted with a low risk of bias, according to the Cochrane critical appraisal list (Table S3) . Both received an allocation-concealment grade of A and a maximum Jadad score of 5. One study 21 reported that physicians and data collectors were not blinded, and received a Jadad score of 3. The fourth study 22 was described in a conference abstract, and did not report allocation concealment, baseline characteristics, withdrawals, or statistical analysis details. It compared methoxyflurane with tramadol, and lacked a bridging comparator between the two compounds of interest: methoxyflurane and N 2 O. It was decided to exclude the latter two studies from the quantitative analysis. The two double-blind, randomized studies included both compared their respective study medication (low-dose methoxyflurane or N 2 O) to placebo; 7, 12 an adjusted indirect comparison was thus used to compare the two treatments. Table 1 lists the main study characteristics. In the first study, patients presenting at six EDs in the UK with at least moderate pain due to minor trauma (physical wound or injury, such as fractures, lacerations, burns, dislocations, contusions, or injury due to foreign bodies) received either low-dose methoxyflurane or placebo for pain relief. 7 For ethical reasons, rescue medication could be requested at any time during and after treatment. The study population included adolescent and adult patients. Data of the adult subgroup were published separately, 8 and are used in this network analysis. The second study setting included ambulances from two firefighter emergency services in France. 12 Patients with moderate traumatic pain received blinded treatment of either N 2 O or medical air (placebo) for the first 15 minutes in the ambulance; thereafter, all placebo patients also received N 2 O. Table 2 provides baseline demographic and clinical characteristics of the patients. The proportion of patients with back trauma was considerably higher in the N 2 O study. Baseline pain intensity was comparable between the studies. Figure 2 shows the comparison between low-dose methoxyflurane and placebo and between N 2 O and placebo for change in pain intensity from baseline, which favored both active treatments at all three time points. The indirect treatment comparison between low-dose methoxyflurane and N 2 O revealed no significant differences between the two agents at 5, 10, or 15 minutes after start of inhalation, although data were in favor of low-dose methoxyflurane (Figure 3) . Figure 4 shows the proportion of patients not experiencing pain relief under low-dose methoxyflurane or N 2 O treatment at 5, 10, and 15 minutes after treatment. Numbers were not significantly different between the two treatments.
Study characteristics
Efficacy outcomes
At 15 minutes, the proportion of patients experiencing pain relief was greater under low-dose methoxyflurane; however, statistical significance could not be achieved.
Safety
Data pertaining to tolerability and safety outcomes were not reported in a similar time frame in the two studies, and thus could not be compared. The N 2 O study evaluated safety at baseline, every 5 minutes for 30 minutes, and then every 15 minutes until arrival at the ED. 12 AEs or withdrawal due to 
Discussion
Low-dose methoxyflurane and N 2 O both provided rapid analgesia for trauma patients in emergency care, with no significant differences between the two agents. The proportion of patients experiencing pain relief at 15 minutes after start of inhalation was greater under low-dose methoxyflurane, but statistical significance was not achieved.
Although both compounds have been used for many years in emergency care, the number of controlled studies was surprisingly small. Head-to-head trials between methoxyflurane and N 2 O in the emergency setting have not been performed; comparative data were only available from an older observational study in volunteers 23 and two studies in dentistry.
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The synthesis of the data identified in our search thus required an indirect approach to treatment comparison. The robustness of such an approach is limited, but indirect analyses offer a first assessment in the absence of head-to-head comparisons. It should be noted that a blinded head-to-head trial of these two agents would not be feasible, due to their properties and delivery methods. Low-dose methoxyflurane is an almost colorless, volatile liquid with a characteristic fruity odor that is vaporized in a handheld inhaler. N 2 O is a homogeneous gas (50:50 mixture with oxygen) compressed into a cylinder that is connected to a demand valve with attached facemask or mouthpiece for delivery to the patient. 25 It should also be noted that different pain scales were used in the two studies: the 100 mm VAS 7 and the NRS, 12 which are not interconvertible. The NRS is a whole-number scale with no intermediate pain scores, whereas the VAS considers point differences as well. However, correlation analyses of acute-pain data obtained in EDs found strong correlations between the NRS and VAS, and showed that they were interchangeable for acute-pain measurement in adult patients. 17, 18 In the present analysis, standardized median differences were computed to limit the risk of variability arising from the use of different assessment scales.
Besides analgesic effectiveness, safety profile and ease of handling (in particular in prehospital settings) will influence the decision on which analgesic to use in emergency care. A comparison of safety data of the two studies included in the indirect treatment analysis was not possible, due to the different time periods analyzed. In the following paragraphs, general safety information for the two compounds is provided.
Low-dose methoxyflurane is contraindicated in patients hypersensitive to the agent or to any fluorinated anesthetics, patients with malignant hyperthermia, patients showing signs of liver damage after previous methoxyflurane use or halogenated hydrocarbon anesthesia, and those with clinically significant renal impairment, an altered level of consciousness, clinically evident cardiovascular instability, or with clinically evident respiratory depression. 5 The most common adverse reactions are related to the central nervous system (eg, dizziness, headache, somnolence) and are mostly transient. Dosages should not exceed 6 mL for a single administration, because methoxyflurane can cause significant nephrotoxicity at high doses. 5 Renal damage probably occurs due to the production of fluoride ions when methoxyflurane is metabolized in the liver and kidneys, 26, 27 and has been reported for anesthetic methoxyflurane doses. 28 However, when used at analgesic doses, the maximum 6 mL of methoxyflurane produce a minimum alveolar concentration (MAC) of 0.59 MAC hours, 29 which is well below the exposure level of >2 MAC hours associated with renal damage. 26 A review by Dayan concluded that methoxyflurane in low-dose analgesic concentrations has a safety margin of at least 2.7-to eightfold based on MAC hours or serum fluoride concentrations. 29 Clinical laboratory evaluations did not indicate any nephrotoxicity in a recent trial in the emergency setting, 7, 8 and a large data-linkage study in the prehospital setting did not observe any increased risk for renal disease in the 17,629 patients administered low-dose methoxyflurane compared to 118,141 patients not receiving methoxyflurane during ambulance transport. 30 Cardiovascular and respiratory parameters were not affected by analgesic methoxyflurane doses in emergency care either, 8, 31 and a retrospective study of case reports of ambulance patients did not show any negative effects of low-dose analgesic concentrations on pulse rate, systolic blood pressure, or respiratory rate. 32 Although the latter study did not find any particular pattern to the patients' systolic blood pressure after low-dose methoxyflurane administration across different age-groups, caution should be exercised in the elderly, due to possible reduction in blood pressure. 5 N 2 O is contraindicated in any condition where gas is entrapped within the body and where expansion might be dangerous. Clinical examples are pneumothorax, air embolism, pneumocephalus, decompression sickness, following a recent dive, following air encephalography, severe bullous emphysema, use during myringoplasty, gross abdominal distension, and in patients who have recently received intraocular gas injections. 25 There is a risk of additive effects when coadministered with centrally acting depressant medications. 25 N 2 O can increase intracranial pressure in patients with head injury, 33 which should preclude its use in traumatic brain injury. The side-effect profile of N 2 O includes dizziness, euphoria, disorientation, sedation, generalized tingling, nausea, and vomiting, which are generally minor and rapidly reversible. 25 A systematic review of the safety of N 2 O in the prehospital setting found that none of the investigated AEs (nausea, vomiting, dizziness, drowsiness, headache, hypotension, and oxygen desaturation) was significantly associated with N 2 O treatment. 34 Low-dose methoxyflurane and N 2 O are both selfadministered, self-titrated, nonnarcotic, noninvasive inhalational agents with similar onset times of pain relief. Both provide rapid and well tolerated analgesia for trauma patients in emergency care, but there are differences regarding ease of administration, handling, and portability. Low-dose methoxyflurane is easily administered via a handheld inhaler, whereas self-administration of N 2 O can be more difficult. Many patients (especially those in pain) do not have the inspiratory capability to trigger the demand valve for successful inhalation of N 2 O. Elderly patients in particular find this difficult, and if edentulous might also encounter problems obtaining a competent fit of the alternative face mask. The small methoxyflurane inhaler is also easier to handle than the heavier and bulkier N 2 O cylinder. Easy portability is especially desired for emergency care in remote or difficultto-reach locations and mass-casualty situations, but is also important for urban/rural paramedics who carry heavy backpacks and in addition often also monitoring equipment. The weighty N 2 O cylinder is thus an additional challenge that should not be underestimated. Furthermore, special precautions for storage are required for N 2 O cylinders. N 2 O is nonflammable, but strongly supports combustion due to the high oxygen concentration within the mixture, and should not be stored near stocks of combustible material. 25 The cylinders also require temperatures above 10°C for at least 24 hours before use to avoid separation of the gas mixture, which could result in hypoxic concentrations being delivered as the cylinder empties.
Conclusion
Low-dose methoxyflurane and N 2 O both provide rapid and well-tolerated analgesia via a noninvasive administration route, and are suitable options for the pain treatment of trauma patients in emergency care. Due to the ease of administration and portability, inhaled low-dose methoxyflurane may not only offer advantages in emergency situations in remote or difficult-to-reach locations and in mass-casualty situations but also be of significant value in urban and rural environments.
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